Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin

Chest

Volumn 130, Issue 6, 2006, Pages 1712-1717

  Lardizabal, Alfred ^a,c   Passannante, Marian ^a   Kojakali, Faysal ^b   Hayden, Christopher ^a   Reichman, Lee B ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

Isoniazid; Latent tuberculosis infection treatment; Rifampin

Indexed keywords

ISONIAZID; RIFAMPICIN;

ABDOMINAL DISCOMFORT; ADOLESCENT; ADULT; ALLERGY; ARTICLE; CHI SQUARE TEST; CHILD; CLINICAL PROTOCOL; CONFIDENCE INTERVAL; DRUG INDICATION; DRUG USE; DRUG WITHDRAWAL; EMPLOYMENT; FEMALE; FISHER EXACT TEST; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEPATITIS; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RANK SUM TEST; RASH; STUDENT T TEST; TREATMENT DURATION; TUBERCULOSIS; UNITED STATES;

EID: 33845930747     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.6.1712     Document Type: Article

References (17)

1. Centers for Disease Control and Prevention. Trends in tuberculosis: United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:245-250
2. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-S247
3. Institute of Medicine. Ending neglect: the elimination of tuberculosis in the United States. In: Geiter L, ed. Committee on the Elimination of Tuberculosis in the United States, Division of Health Promotion and Disease Prevention, Institute of Medicine. Washington, DC: National Academy Press, 2000
4. Jordan TJ, Lewitt EM, Montgomery RL, et al. Isoniazid as preventive therapy in HIV infected intravenous drug abusers. JAMA 1991; 265:2987-2991
5. International Union Against Tuberculosis and Lung Disease, Anti-tuberculosis drug resistance in the world: report No. 3. Geneva, Switzerland: World Health Organization, 2004
6. LoBue P, Moser K. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168:443-447
7. Dear colleague letter from Dr. Kenneth Castro, Director, Division of Tuberculosis Elimination, Atlanta, GA: Centers for Disease Control and Prevention, 2006
8. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:735-739
9. Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. N Engl J Med 2003; 347:1860-1866
10. Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2004; 170:832-835
11. Menzies RI, Dion M, Rabinovitch B, et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170:445-449
12. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short course chemotherapy with rifampin and pyrazinamide, Am Rev Respir Dis 1989; 140:1189-1193
13. Dhillon J, Dickinson JM, Sole K, et al. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 1996; 40:552-555
14. Hong Kong Chest Service, Tuberculosis Research Centre, Madras, and BMJ Research Council. 1992. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145:36-41
15. Polesky A, Farber HW, Gottlieb DJ, et al. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996; 154:1473-1477
16. Villarino M, Ridzon R, Weismuller P, et al. Rifampin preventive therapy for tuberculosis infection. Am J Respir Crit Care Med 1997; 155:173.5-1738
17. American Academy of Pediatrics. Tuberculosis. In: Pickering LK, ed. Red Book: 2003; Report of the Committee on Infectious Diseases, 26th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2003; 652